Alnylam Pharmaceuticals, Inc.
ALNY · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | -$278,157 | -$440,242 | -$1,131,156 | -$852,824 |
| Dep. & Amort. | $56,670 | $97,031 | $85,550 | $89,694 |
| Deferred Tax | -$106,762 | $0 | $0 | -$55,695 |
| Stock-Based Comp. | $272,084 | $221,680 | $230,649 | $165,717 |
| Change in WC | -$214,084 | $10,759 | -$35,553 | -$162,823 |
| Other Non-Cash | $261,937 | $214,928 | $309,236 | $174,238 |
| Operating Cash Flow | -$8,312 | $104,156 | -$541,274 | -$641,693 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -$34,277 | -$62,211 | -$72,059 | -$76,372 |
| Net Acquisitions | $0 | $0 | $0 | $0 |
| Inv. Purchases | -$1,711,986 | -$1,823,501 | -$1,976,961 | -$1,656,114 |
| Inv. Sales/Matur. | $1,571,665 | $1,553,800 | $2,231,568 | $1,463,550 |
| Other Inv. Act. | $57,758 | -$4,438 | -$13,194 | -$4,364 |
| Investing Cash Flow | -$116,840 | -$336,350 | $169,354 | -$273,300 |
| Financing Activities | – | – | – | – |
| Debt Repay. | $0 | $0 | $254,004 | $500,000 |
| Stock Issued | $302,951 | $147,464 | $259,360 | $246,268 |
| Stock Repurch. | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 |
| Other Fin. Act. | -$8,792 | $24,667 | -$87,611 | $500,850 |
| Financing Cash Flow | $294,159 | $172,131 | $425,753 | $1,247,118 |
| Forex Effect | -$15,239 | $6,391 | -$7,430 | -$9,018 |
| Net Chg. in Cash | $153,768 | -$53,672 | $46,403 | $323,107 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $814,884 | $868,556 | $822,153 | $499,046 |
| End Cash | $968,652 | $814,884 | $868,556 | $822,153 |
| Free Cash Flow | -$42,589 | $41,945 | -$613,333 | -$718,065 |